[Deep brain stimulation for Parkinson's disease: timing and patient selection].
Deep brain stimulation (DBS) is an effective and evidence-based treatment option for Parkinson's disease. Studies have shown that DBS has good and long-term effects on motor function and quality of life for patients in an advanced stage of the disease and that it is more effective than medical therapy alone. Moreover, a favorable effect of DBS could also be detected at an earlier stage of the disease. On the other hand, possible risks and side effects of the procedure need to be taken into consideration. These can manifest as procedure-related complications, such as bleeding and infections in addition to stimulation-associated phenomena, such as neuropsychiatric disorders and motor side effects. Despite the good effects of DBS important issues still need to be addressed which will be discussed in this article considering the results of several new randomized and controlled clinical studies. For patients with Parkinson's disease with early fluctuations and dyskinesia, DBS has been found to be superior to the best pharmaceutical treatment; therefore, DBS can be considered as a treatment option in the earlier course of the disease. The diagnostic evaluation and the exclusion of contraindications are crucial for patient selection. The choice of the target should be based on the individual symptoms in patients although the subthalamic nucleus (STN) can be considered the standard target. In every case an individual assessment of chances and risks must be conducted and realistic goals and reasonable expectations must be defined.
Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Christian Albrechts Universität Kiel, Haus 41, Arnold-Heller-Str., 24105, Kiel, Deutschland, r.erasmi@neurologie.uni-kiel.de.
R
R
Erasmi
G
G
Deuschl
K
K
Witt
D046690:Deep Brain Stimulation / Q000379:methods*; D020820:Dyskinesias / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D010358:Patient Participation / Q000379:methods*; D018579:Patient Selection; D018570:Risk Assessment; D016896:Treatment Outcome